Prognostic Utility of dNLR, ALRI, APRI, and SII in COVID-19 Patients with Diabetes: A Cross-Sectional Study
Open Access
- 4 August 2024
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 14 (15) , 1685
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has necessitated the identification of biomarkers that can predict disease severity, particularly in vulnerable populations such as individuals with diabetes. This study aims to evaluate the predictive value of inflammatory and liver function markers, specifically derived Neutrophil to Lymphocyte Ratio (dNLR), aspartate aminotransferase (AST)-to-lymphocyte ratio (ALRI), AST to Platelet Ratio Index (APRI), and Systemic Inflammation Index (SII), in COVID-19 patients with and without diabetes. This cross-sectional study included 336 participants, comprising 168 patients with diabetes matched with 168 without, based on gender, body mass index (BMI), and COVID-19 severity at hospitalization. The study was conducted at Victor Babes Hospital for Infectious Diseases and Pulmonology from January 2021 to December 2023. All participants had a confirmed SARS-CoV-2 infection and met the inclusion criteria of being 18 years or older with type 1 or type 2 diabetes as per American Diabetes Association guidelines. At 3 days post symptom onset, significant differences in inflammatory and liver function markers were observed between the two groups. The dNLR, ALRI, APRI, and SII were notably higher in diabetic patients. At a dNLR cutoff of 2.685, the sensitivity and specificity were 70.312% and 65.978%, respectively, with an AUC of 0.624 (p < 0.001). The ALRI showed a cutoff of 0.812, with a sensitivity of 76.429% and specificity of 69.541% (AUC 0.752, p < 0.001). These markers demonstrated statistically significant hazard ratios at both 3 and 7 days, indicating their predictive relevance for severe COVID-19 outcomes. For instance, at 7 days, SII demonstrated a hazard ratio of 2.62 (CI: 1.29–5.04, p < 0.001), highlighting its strong prognostic capability. The study successfully identified significant differences in inflammatory and liver function markers between COVID-19 patients with and without diabetes, with these markers showing good predictive value for disease severity. The results underscore the potential of these biomarkers, particularly ALRI and SII, as valuable tools in managing COVID-19, aiding in the timely identification of patients at increased risk of severe outcomes.Keywords
Funding Information
- Victor Babes University of Medicine and Pharmacy Timisoara
This publication has 33 references indexed in Scilit:
- Lessons learnt from COVID-19 to reduce mortality and morbidity in the Global South: addressing global vaccine equity for future pandemicsBMJ Global Health, 2024
- Role of inflammation in determining the severity of COVID-19 infection in patients with diabetes: A comparative studyMedicine, 2023
- Clinical utility of inflammatory biomarkers in COVID‐19‐related sudden sensorineural hearing lossImmunity, Inflammation and Disease, 2023
- Placental oxidative stress and monoamine oxidase expression are increased in severe preeclampsia: a pilot studyMolecular and Cellular Biochemistry, 2022
- Plasma glucose levels and diabetes are independent predictors for mortality in patients with COVID-19Epidemiology and Infection, 2022
- Impairment of mitochondrial respiration in platelets and placentas: a pilot study in preeclamptic pregnanciesMolecular and Cellular Biochemistry, 2022
- Predictive Value of Systemic Immune-Inflammation index and Neutrophil-to-Lymphocyte Ratio in Patients with Severe COVID-19Clinical and Applied Thrombosis/Hemostasis, 2022
- Diabetes Mellitus and COVID-19: Associations and Possible MechanismsInternational Journal of Endocrinology, 2021
- A Review on Oxidative Stress, Diabetic Complications, and the Roles of Honey PolyphenolsOxidative Medicine and Cellular Longevity, 2020
- Peripheral blood inflammatory markers in predicting prognosis in patients with COVID‐19. Some differences with influenza AJournal of Clinical Laboratory Analysis, 2020